REPL insider filings
Replimune Group, Inc. — 50 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2026-11-18. Screen REPL transaction legs live →
Insider transaction summary — last 90 days
2026-08-23 to 2026-11-21, from the filings listed below: 7 insider filings (Forms 3/4/5). Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 6 legs across 6 filings by 6 insiders — 108,781 shares, $2,294,810 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 3.
- Largest priced transaction: sale of 49,026 shares @ $21.60 ($1,058,962) by Patel Sushil, filed 2026-11-18.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Patel Sushil — Chief Executive Officer, Director | 1 | — | 1 leg · 49,026 sh · $1,058,962 | — |
| Dhingra Kapil — Director | 1 | — | 1 leg · 21,500 sh · $408,500 | 2 |
| Xynos Konstantinos — Chief Medical Officer | 1 | — | 1 leg · 16,198 sh · $349,877 | — |
| Hill Emily Luisa — Chief Financial Officer | 1 | — | 1 leg · 14,709 sh · $317,714 | — |
| SLATTERY JOSEPH P — Director | 1 | — | 1 leg · 5,200 sh · $113,360 | — |
| Schwendenman Andrew — Chief Accounting Officer | 1 | — | 1 leg · 2,148 sh · $46,397 | — |
| Astley-Sparke Philip — Director | 1 | — | — | 1 |
Recent insider filings — Replimune Group, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-18 | 4 | Schwendenman Andrew — Chief Accounting Officer | Sale (S): 2,148 @ $21.60 | EDGAR |
| 2026-11-18 | 4 | Hill Emily Luisa — Chief Financial Officer | Sale (S): 14,709 @ $21.60 | EDGAR |
| 2026-11-18 | 4 | Patel Sushil — Chief Executive Officer, Director | Sale (S): 49,026 @ $21.60 | EDGAR |
| 2026-11-18 | 4 | Xynos Konstantinos — Chief Medical Officer | Sale (S): 16,198 @ $21.60 | EDGAR |
| 2026-11-10 | 4 | SLATTERY JOSEPH P — Director | Sale (S): 5,200 @ $21.80 | EDGAR |
| 2026-11-03 | 4 | Dhingra Kapil — Director | Option exercise (M): 43,169 @ $1.75 · Sale (S): 21,500 @ $19 · Option exercise (M): 43,169 (derivative) @ $0 | EDGAR |
| 2026-08-24 | 4 | Astley-Sparke Philip — Director | Gift (G): 50,000 @ $0 | EDGAR |
| 2026-08-19 | 4 | Hill Emily Luisa — Chief Financial Officer | Sale (S): 9,256 @ $14.28 | EDGAR |
| 2026-08-12 | 4 | Xynos Konstantinos — Chief Medical Officer | Sale (S): 11,447 @ $12.97 | EDGAR |
| 2026-08-12 | 4 | Hill Emily Luisa — Chief Financial Officer | Sale (S): 11,448 @ $12.97 | EDGAR |
| 2026-08-12 | 4 | Patel Sushil — Chief Executive Officer, Director | Sale (S): 39,341 @ $12.97 | EDGAR |
| 2026-08-12 | 4 | Schwendenman Andrew — Chief Accounting Officer | Sale (S): 7,632 @ $12.97 | EDGAR |
| 2026-08-11 | 4 | BAKER BROS. ADVISORS LP — Director, 10% owner Baker Bros. Advisors (GP) LLC — Director, 10% owner 667, L.P. — Director, 10% owner Baker Brothers Life Sciences LP — Director, 10% owner BAKER FELIX — Director, 10% owner BAKER JULIAN — Director, 10% owner | Purchase (P): 126,394 (derivative) @ $12.06 · Purchase (P): 2,609,946 (derivative) @ $12.06 | EDGAR |
| 2026-06-03 | 4 | Sarchi Christopher — Chief Commercial Officer | Sale (S): 12,000 @ $9.24 | EDGAR |
| 2026-05-20 | 4 | Xynos Konstantinos — Chief Medical Officer | Sale (S): 14,023 @ $5.08 | EDGAR |
| 2026-05-20 | 4 | Schwendenman Andrew — Chief Accounting Officer | Sale (S): 7,894 @ $5.08 | EDGAR |
| 2026-05-20 | 4 | Sarchi Christopher — Chief Commercial Officer | Sale (S): 8,626 @ $5.08 | EDGAR |
| 2026-05-20 | 4 | Patel Sushil — Chief Executive Officer, Director | Sale (S): 37,324 @ $5.08 | EDGAR |
| 2026-05-20 | 4 | Hill Emily Luisa — Chief Financial Officer | Sale (S): 7,812 @ $5.08 | EDGAR |
| 2026-05-20 | 4 | Astley-Sparke Philip — Director | Sale (S): 17,657 @ $5.08 | EDGAR |
| 2026-04-07 | 4 | Sarchi Christopher — Chief Commercial Officer | Grant/award (A): 50,000 @ $0 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Oliger Christy J. — Director | Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Xynos Konstantinos — Chief Medical Officer | Grant/award (A): 50,000 @ $0 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Schwendenman Andrew — Chief Accounting Officer | Grant/award (A): 36,667 @ $0 · Grant/award (A): 55,000 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Patel Sushil — Chief Executive Officer, Director | Grant/award (A): 251,240 @ $0 · Grant/award (A): 376,860 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Peeples-Dyer Veleka — Director | Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Hill Emily Luisa — Chief Financial Officer | Grant/award (A): 50,000 @ $0 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Weinand Dieter — Director | Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Balachandran Madhavan — Director | Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Dhingra Kapil — Director | Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Pucci Paolo — Director | Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | Astley-Sparke Philip — Director | Grant/award (A): 50,000 @ $0 · Grant/award (A): 75,000 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | SLATTERY JOSEPH P — Director | Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2026-04-07 | 4 | BAKER BROS. ADVISORS LP — Director, 10% owner Baker Bros. Advisors (GP) LLC — Director, 10% owner 667, L.P. — Director, 10% owner Baker Brothers Life Sciences LP — Director, 10% owner BAKER FELIX — Director, 10% owner BAKER JULIAN — Director, 10% owner | Grant/award (A): 44,500 (derivative) @ $0 · Grant/award (A): 44,500 (derivative) @ $0 | EDGAR |
| 2026-04-06 | 4 | Sarchi Christopher — Chief Commercial Officer | Sale (S): 6,500 @ $8.01 | EDGAR |
| 2026-02-20 | 4 | Astley-Sparke Philip — Director | Gift (G): 25,000 @ $0 | EDGAR |
| 2025-12-19 | 4 | Patel Sushil — Chief Executive Officer, Director | Grant/award (A): 200,000 @ $0 | EDGAR |
| 2025-12-19 | 4 | Xynos Konstantinos — Chief Medical Officer | Grant/award (A): 60,000 @ $0 | EDGAR |
| 2025-12-19 | 4 | Hill Emily Luisa — Chief Financial Officer | Grant/award (A): 60,000 @ $0 | EDGAR |
| 2025-12-19 | 4 | Sarchi Christopher — Chief Commercial Officer | Grant/award (A): 35,000 @ $0 | EDGAR |
| 2025-12-19 | 4 | Schwendenman Andrew — Chief Accounting Officer | Grant/award (A): 10,000 @ $0 | EDGAR |
| 2025-12-11 | 4 | Dhingra Kapil — Director | Option exercise (M): 3,169 @ $1.75 · Sale (S): 3,169 @ $10.40 · Option exercise (M): 3,169 (derivative) @ $0 | EDGAR |
| 2025-12-04 | 4 | Patel Sushil — Chief Executive Officer, Director | Sale (S): 10,000 @ $11.13 | EDGAR |
| 2025-11-19 | 4 | Sarchi Christopher — Chief Commercial Officer | Sale (S): 5,208 @ $9.10 | EDGAR |
| 2025-11-19 | 4 | Xynos Konstantinos — Chief Medical Officer | Sale (S): 7,248 @ $9.10 | EDGAR |
| 2025-08-19 | 4 | Hill Emily Luisa — Chief Financial Officer | Sale (S): 9,154 @ $5.37 | EDGAR |
| 2025-05-22 | 4 | Patel Sushil — Chief Executive Officer, Director | Sale (S): 25,105 @ $8.06 | EDGAR |
| 2025-05-22 | 4 | Hill Emily Luisa — Chief Financial Officer | Sale (S): 2,535 @ $8.05 | EDGAR |
| 2025-05-22 | 4 | Sarchi Christopher — Chief Commercial Officer | Sale (S): 3,749 @ $8.05 | EDGAR |
| 2025-05-22 | 4 | Astley-Sparke Philip — Director | Sale (S): 32,279 @ $8.06 | EDGAR |
Recent 8-K events — Replimune Group, Inc.
Items classified from EDGAR index headers. Browse recent 8-K filings market-wide, by item code →
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-10-28 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-16 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-11 | 8-K/A | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-10 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-07 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-31 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-30 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-29 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-26 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=REPL returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. Get a free API key → · API docs